Compare UPBD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | PHAT |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2019 |
| Metric | UPBD | PHAT |
|---|---|---|
| Price | $19.81 | $12.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $32.25 | $17.33 |
| AVG Volume (30 Days) | 631.5K | ★ 988.1K |
| Earning Date | 02-19-2026 | 03-05-2026 |
| Dividend Yield | ★ 7.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $4,577,844,000.00 | $147,190,000.00 |
| Revenue This Year | $10.33 | $221.87 |
| Revenue Next Year | $7.55 | $80.37 |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | 7.48 | ★ 460.30 |
| 52 Week Low | $15.82 | $2.21 |
| 52 Week High | $30.20 | $18.31 |
| Indicator | UPBD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 35.59 |
| Support Level | $19.40 | $12.22 |
| Resistance Level | $20.84 | $13.18 |
| Average True Range (ATR) | 0.74 | 0.80 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 54.62 | 7.91 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.